Results 121 to 130 of about 402,235 (309)

Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas

Annals of Neurology, EarlyView.
Objective Mitogen‐activated protein kinase kinase inhibitors have shown promising results in treatment of plexiform neurofibromas in neurofibromatosis type 1 patients, but data in adults are limited. The aim of this phase 2 study was to investigate the efficacy and safety of trametinib in adults with neurofibromatosis type 1.
D. Christine Noordhoek, David F. Hanff, Pim J. French, Sarah A. van Dijk, Erik A.C. Wiemer, Olivier C. Manintveld, Martin J. van den Bent, Walter Taal   +7 more
wiley   +1 more source

Back Again to the Future: A New Era for Cerebroprotection

Annals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

Placebo, nocebo: Believing in the field of medicine

Frontiers in Pain Research, 2022
Karin Meissner, Karin Meissner
doaj   +1 more source

Harnessing the placebo effect to enhance emotion regulation effectiveness and choice. [PDF]

Sci Rep, 2023
Shafir R, Israel M, Colloca L.
europepmc   +1 more source

Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large‐Scale, Multi‐Cohort Proteomic Study

Annals of Neurology, EarlyView.
Objective Biomarkers with clear contexts of use are important tools for amyotrophic lateral sclerosis (ALS) therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response.
Oleksandr Dergai, Joanne Wuu, Magdalena Koziczak‐Holbro, Andrea Malaspina, Volkan Granit, Jessica P. Hernandez, Anne Cooley, Ruchika Sachdev, Lili Yu, Michael Bidinosti, Ludivine Flotte, Mark Nash, Lori L. Jennings, James D. Berry, Lucie I. Bruijn, Sophie Brachat, Michael Benatar   +16 more
wiley   +1 more source

Cold water immersion after a soccer match: Does the placebo effect occur? [PDF]

Front Physiol, 2023
Nasser N, Zorgati H, Chtourou H, Guimard A.   +3 more
europepmc   +1 more source

Placebos and Placebo Effects [PDF]

Anaesthesia and Intensive Care, 2010
openaire   +1 more source

964 Is the Placebo Effect Revealable in Newborns? Results from an RCT in Osteopathy [PDF]

, 2012
Francesco Cerritelli, Gina Barlafante, Cinzia Renzetti, Franco Ricci, N. Loprete, Gianfranco Pizzolorusso, Paola Fusilli, Carmine D’Incecco   +7 more
openalex   +1 more source

Distortion in the Communication of Nonsignificant Primary Outcomes: The Spin Strategy in Multiple Sclerosis Trials

Annals of Neurology, EarlyView.
Objective Spin refers to reporting strategies that highlight the benefits of an experimental treatment or divert attention from nonsignificant primary outcomes. To assess spin in randomized clinic trials (RCTs) on pharmaceutical efficacy in multiple sclerosis (MS) and explore associated factors.
Marta Mascareñas‐García, Alejandro Rivero‐de‐Aguilar, Cristina Candal‐Pedreira, Guadalupe García, Carla Guerra‐Tort, Lucía Martín‐Gisbert, Julia Rey‐Brandariz, Mónica Pérez‐Ríos Ríos, Beatriz Casal‐Acción, María Isolina Santiago‐Pérez, Leonor Varela‐Lema   +10 more
wiley   +1 more source

Intranasal Seletracetam in a Patient with Reading Epilepsy: First‐in‐Human Use to Prevent Reflex Seizures

Annals of Neurology, EarlyView.
We report the first human use of intranasal seletracetam (SEL) to prevent reflex seizures. A patient with epilepsy with reading‐induced seizures on levetiracetam (3,000 mg/day) continued to experience reading‐induced focal seizures with preserved consciousness.
Matthias J. Koepp, Kai‐Nicolas Poppert, Thomas Felder, Aljoscha Thomschewski, Sandra Lafenthaler, Pavel Klein, Alexander Rotenberg, Wolfgang Löscher, Chris Rundfeldt, Eugen Trinka   +9 more
wiley   +1 more source